Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Liabilities and Shareholders Equity (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $185.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 38.01% to $185.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $914.2 million, a 35.17% decrease, with the full-year FY2025 number at $185.0 million, down 38.01% from a year prior.
  • Liabilities and Shareholders Equity was $185.0 million for Q4 2025 at Lexicon Pharmaceuticals, down from $205.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $417.2 million in Q1 2024 to a low of $162.7 million in Q1 2023.
  • A 3-year average of $275.8 million and a median of $287.1 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 156.41% in 2024, then tumbled 39.58% in 2025.
  • Lexicon Pharmaceuticals' Liabilities and Shareholders Equity stood at $229.4 million in 2023, then skyrocketed by 30.07% to $298.4 million in 2024, then tumbled by 38.01% to $185.0 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Liabilities and Shareholders Equity are $185.0 million (Q4 2025), $205.9 million (Q3 2025), and $225.6 million (Q2 2025).